Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative research at NIMHANS.

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a $13.6 billion biopharmaceutical company with strong financial health according to InvestingPro metrics, presented new three-year data showing ...

SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT ®-HD2 study demonstrating an established long-term safety ...

The United States Huntington's Disease Treatment Market is set to expand significantly, with an expected CAGR of 15.22% from ...

However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...

SOM Biotech, a clinical-stage company dedicated to the discovery and development of innovative therapies for rare central nervous system disorders, announces today that it has received the final ...

Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval, BioSpace looks at ...

Analysts are estimating that Neurocrine Biosciences will report an earnings per share (EPS) of $1.87. Neurocrine Biosciences ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares rose 3.3% after the neuroscience-focused biopharmaceutical company reported third-quarter financial results that significantly exceeded ...